Inovio Pharmaceuticals, Inc. (INO)
| Market Cap | 1.44B |
| Revenue (ttm) | 6.46M |
| Net Income (ttm) | -188.27M |
| Shares Out | 202.41M |
| EPS (ttm) | -1.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 10 |
| Last Price | $6.67 |
| Previous Close | $6.85 |
| Change ($) | -0.18 |
| Change (%) | -2.63% |
| Day's Open | 7.01 |
| Day's Range | 6.61 - 7.20 |
| Day's Volume | 16,053,518 |
| 52-Week Range | 6.23 - 33.79 |
PLYMOUTH MEETING, Pa., May 10, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from i...
PLYMOUTH MEETING, Pa., May 10, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectiou...
PLYMOUTH MEETING, Pa., May 4, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious...
Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts believe these underperformers could nearly double over the next 12 months.
It might be able to, although it won't be easy.
PLYMOUTH MEETING, Pa., April 27, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that first quarter 2021 financial results will be released after the market close on May 10, 2021.
These tiny stocks could pack big-time return potential, if analysts are correct.
Everything may depend on an early-stage program.
There's real value in being a first-mover.
Inovio Pharmaceuticals said Friday the Department of Defense pulled its funding for final-phase testing of the company's Covid vaccine and device, prompting INO stock to collapse. The post Inovio Stock ...
The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.
Novavax, Inc. (NASDAQ: NVAX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and Protara Therapeutics, Inc. (NASDAQ: TARA) are among the biotech movers Friday. Novavax Moves On Mid-stage Malaria Vaccine Dat...
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares dived in the premarket in reaction to the company's plans for a predominantly ex-U.S. Phase 3 trial for its COVID-19 vaccine candidate, INO-4800. Given th...
PLYMOUTH MEETING, Pa., April 23, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infecti...
It's all about the ultimate coronavirus vaccine.
PPD, Inc. (NASDAQ: PPD), Immunic, Inc. (NASDAQ: IMUX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and CureVac N.V. (NASDAQ: CVAC) are among the healthcare movers on Thursday.
PLYMOUTH MEETING, Pa., April 15, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from...
Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigatio...
It has to do with game-changing technology.
Inovio has thrown its hat into the coronavirus vaccine ring with big biopharma names like Moderna, Johnson & Johnson and Pfizer. But INO stock is volatile on its vaccine news.
We believe that Inovio Pharmaceuticals , a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, is a good buying opportunity at the present time. INO sto...
Inovio Pharmaceuticals, Inc. (NASDAQ: INO), which has fallen behind in the COVID-19 vaccine race, has much to offer beyond a coronavirus vaccine, according to a BofA Securities analyst. The Inovio Anal...
Let's look at what some of the smartest investors are saying.
Why? They're focusing on one of the biggest coronavirus problems.
Although these stocks are popular with the Reddit community, they're bad news.
PLYMOUTH MEETING, Pa., March 15, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infecti...
The biotech could be a winner over the long run but faces some significant challenges.
There was one big wrinkle with the biotech's study.
INO stock is poised to fall further as the chances of a vaccine approval fall and its competitors widen their lead The post Sell Inovio While You Still Can appeared first on InvestorPlace. More From Inv...
The stock price of Inovio Pharmaceuticals, a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, has seen a large 27% drop over the last ten trading day...
PLYMOUTH MEETING, Pa., March 3, 2021 /PRNewswire/ -- Geneos Therapeutics, a clinical stage company focused on the development of tumor neoantigen targeted personalized immunotherapies for cancer, announ...
Investors still appear to have doubts about two of the biotech's lead candidates.
Better-than-expected top- and bottom-line results weren't enough.
These are the stocks posting the largest moves after the bell on Monday, March 1.
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are lower in after-hours trading in reaction to multiple catalysts. REVEAL 1 Study Reveals Mixed Results In Cervical Dysplasia: Inovio said a pivotal REVE...
Shares of Inovio Pharmaceuticals (NASDAQ:INO) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 63.16% over the past year to ($0.1...
PLYMOUTH MEETING, Pa., March 1, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from...
On Monday, March 01, Inovio Pharmaceuticals (NASDAQ:INO) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.
Inovio (INO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Qiagen NV (NYSE: QGEN) and Inovio Pharmaceuticals Inc (NASDAQ: INO) expanded their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products usin...
PLYMOUTH MEETING, Pa. and GERMANTOWN, Md. and HILDEN, Germany, Feb. 24, 2021 /PRNewswire/ -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced a...
Inovio (INO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
On Inovio's (INO) fourth-quarter earnings call, investor focus will be on updates on the company's progress with the development of its COVID-19 vaccine candidate, INO-4800.
This straggler in the vaccine race is still facing some struggles -- but there are a couple of bright spots.
Inovio Pharmaceuticals (INO) closed the most recent trading day at $13.84, moving -0.93% from the previous trading session.
The choice isn't easy, but simplicity may be the answer.
Shares of coronavirus vaccine developer Inovio Pharmaceuticals Inc (NASDAQ: INO) were surging Friday after a vote of confidence from the Street. Bullish Analyst, Fund Stake Prop Up Stock: Oppenheimer a...
About INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system's tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants. The company is involved in conducting an... [Read more...]
| Industry Biotechnology | IPO Date Feb 12, 1998 |
| CEO Jong Kim | Employees 262 |
| Stock Exchange NASDAQ | Ticker Symbol INO |
Financial Performance
In 2020, INO's revenue was $7.41 million, an increase of 80.24% compared to the previous year's $4.11 million. Losses were -$166.41 million, 39.4% more than in 2019.
Analyst Forecasts
According to 8 analysts, the average rating for INO stock is "Hold." The 12-month stock price forecast is 14.63, which is an increase of 119.34% from the latest price.